このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Xenetic Biosciences 将来の成長

Future 基準チェック /26

Xenetic Biosciencesの収益は年間32.4%で減少すると予測されていますが、年間収益は年間34.1%で増加すると予想されています。EPS は年間29.8%で増加すると予想されています。

主要情報

-32.4%

収益成長率

29.8%

EPS成長率

Biotechs 収益成長	28.2%
収益成長率	34.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	20 Aug 2024

今後の成長に関する最新情報

Recent updates

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Dec 15

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Dec 01

Xenetic Biosciences reports Q2 results

Aug 12

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Aug 02

Xenetic inks clinical manufacturing contract with Catalent

Jul 07

Xenetic Biosciences reports Q3 results

Nov 13

業績と収益の成長予測

NasdaqCM:XBIO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2	-15	N/A	N/A	1
12/31/2025	2	-9	N/A	N/A	1
12/31/2024	2	-6	N/A	N/A	1
6/30/2024	3	-5	-3	-3	N/A
3/31/2024	2	-4	-4	-4	N/A
12/31/2023	3	-4	-4	-4	N/A
9/30/2023	2	-4	-4	-4	N/A
6/30/2023	2	-4	-4	-4	N/A
3/31/2023	2	-6	-4	-4	N/A
12/31/2022	2	-7	-5	-5	N/A
9/30/2022	2	-7	-6	-5	N/A
6/30/2022	1	-7	-6	-5	N/A
3/31/2022	1	-6	-5	-5	N/A
12/31/2021	1	-6	-5	-5	N/A
9/30/2021	1	-5	-4	-4	N/A
6/30/2021	1	-11	-4	-4	N/A
3/31/2021	1	-11	-5	-5	N/A
12/31/2020	0	-11	-4	-4	N/A
9/30/2020	0	-11	-5	-5	N/A
6/30/2020	0	-14	-6	-6	N/A
3/31/2020	0	-14	-6	-6	N/A
12/31/2019	0	-18	-6	-6	N/A
9/30/2019	N/A	-19	-6	-6	N/A
6/30/2019	N/A	-10	-5	-5	N/A
3/31/2019	N/A	-11	-6	-6	N/A
12/31/2018	N/A	-7	-6	-6	N/A
9/30/2018	8	-1	-1	-1	N/A
6/30/2018	8	-2	-1	-1	N/A
3/31/2018	8	-3	N/A	0	N/A
12/31/2017	8	-4	N/A	1	N/A
9/30/2017	3	-12	N/A	-8	N/A
6/30/2017	3	-13	N/A	-7	N/A
3/31/2017	3	-58	N/A	-7	N/A
12/31/2016	3	-58	N/A	-9	N/A
9/30/2016	N/A	-57	N/A	-5	N/A
6/30/2016	N/A	-60	N/A	-6	N/A
3/31/2016	N/A	-14	N/A	-5	N/A
12/31/2015	N/A	-13	N/A	-5	N/A
9/30/2015	N/A	-13	N/A	-7	N/A
6/30/2015	N/A	-11	N/A	-8	N/A
3/31/2015	N/A	-13	N/A	-11	N/A
12/31/2014	N/A	-14	N/A	-13	N/A
9/30/2014	N/A	-14	N/A	-12	N/A
6/30/2014	N/A	-13	N/A	-12	N/A
3/31/2014	1	-11	N/A	-9	N/A
12/31/2013	1	-9	N/A	-6	N/A
9/30/2013	1	-7	N/A	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: XBIO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: XBIO今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: XBIO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: XBIOの収益 ( 34.1% ) US市場 ( 8.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: XBIOの収益 ( 34.1% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: XBIOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Xenetic Biosciences 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased to US$4.00

Consensus forecasts updated

Consensus EPS estimates increase to -US$0.55

Price target increased to US$5.00

Recent updates

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Xenetic Biosciences, Inc. Announces the Appointment of James Parslow as Interim Chief Executive Officer

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CLS Therapeutics Discloses its Views on Xenetic Biosciences

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform

Xenetic Biosciences, Inc., Annual General Meeting, Dec 06, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Xenetic Biosciences, Inc., Annual General Meeting, Dec 21, 2022

Xenetic Biosciences Receives a Non-Compliance Letter from Nasdaq

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board

Price target increased to US$4.00

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xenetic Biosciences, Inc., Annual General Meeting, Dec 07, 2022

Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, Inc.

Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Xenetic Biosciences reports Q2 results

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Xenetic inks clinical manufacturing contract with Catalent

Xenetic Biosciences Receives Written Notification from the Listing Qualifications Department of the Nasdaq

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Xenetic Biosciences, Inc. announced that it has received $0.86625 million in funding

High number of new directors

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$1.20 loss in 3Q 2020)

Consensus EPS estimates increase to -US$0.55

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.15 loss in 2Q 2020)

Price target increased to US$5.00

Xenetic Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

Xenetic Biosciences reports Q3 results

Xenetic Biosciences Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘